MedEdTalks - Oncology podcast

Player FM - Internet Radio Done Right

تمت الإضافة منذ قبل four أعوام

المحتوى المقدم من Vindico Medical Education, Owen A. O'Connor, and MD. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Vindico Medical Education, Owen A. O'Connor, and MD أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.

The So What from BCG

1
Re-Recruiting and Other New HR Strategies You Can’t Ignore 18:09

منذ 9 أيام18:09

التشغيل لاحقا

قوائم

إعجاب

احب

18:09

HR is no longer just about managing people—it’s about shaping the future of work. Jens Baier, BCG’s HR transformation expert, discusses how AI and shifting employee expectations are forcing companies to rethink talent strategies. From re-recruiting to upskilling employees, HR must adapt to a rapidly changing landscape. Learn More: Jens Baier: https://on.bcg.com/41ca7Gv BCG on People Strategy: https://on.bcg.com/3QtAjro Decoding Global Talent: https://on.bcg.com/4gUC4IT…

MedEdTalks - Oncology

منزل السلاسل•Feed

MedEdTalks Oncology is a continuing medical education podcast for physicians to allow them to learn while on the go and obtain CME credits. This show will focus in on different oncology topics, starting with PTCL. In the first season, we will be talking with Dr. Owen O'Connor from Columbia University in New York City, Dr. Tim Illidge from University of Manchester in the United Kingdom and Dr. Lorenz Trumper from Göttingen University in Germany.

14 حلقات

#Science #Fitness #Medicine #Vindico Medical Education #Owen A. O'Connor #Lorenztrumper #Oncology #Owenoconnor #Ptcl #Timillidge #CME #MedEdTalks

MedEdTalks - Oncology

updated منذ عامين

منزل السلاسل•Feed

14 حلقات

#Science #Fitness #Medicine #Vindico Medical Education #Owen A. O'Connor #Lorenztrumper #Oncology #Owenoconnor #Ptcl #Timillidge #CME #MedEdTalks

كل الحلقات

MedEdTalks - Oncology

1
Case Studies on the Use of IO in NSCLC With Drs. Jeffrey Kern and Laurie Carr 24:26

منذ 2 years24:26

24:26

MedEdTalks - Oncology

1
Updates on the Use of Neoadjuvant and Adjuvant IO in Patients With NSCLC With Drs. Laurie Carr and Heather Wakelee 15:48

منذ 2 years15:48

15:48

MedEdTalks - Oncology

1
Updates in IO for Advanced NSCLC – Options for First-line Treatment and Management of Progressive Disease With Drs. Laurie Carr and Heather Wakelee 18:58

منذ 2 years18:58

18:58

MedEdTalks - Oncology

1
NSCLC: Updates in Testing and Interpreting Results – Focus on IO With Drs. Laurie Carr and David Ross Camidge 18:44

منذ 2 years18:44

18:44

MedEdTalks - Oncology

1
NSCLC: Optimizing Care Coordination – Through the Patient and Caregiver’s Eyes 27:59

منذ 2 years27:59

27:59

MedEdTalks - Oncology

1
Lung Cancer Advances and Challenges During a Pandemic – Where Do We Go From Here? With Drs. Jeffrey Kern and Charu Aggarwal 26:11

منذ 2 years26:11

26:11

MedEdTalks - Oncology

1
Improving Provider Confidence in Patient Identification and the Administration of Oncolytic Viral Therapy With Drs. Howard Kaufman and Anna Pavlick 15:35

منذ 4 years15:35

15:35

Within this podcast, Improving Provider Confidence in Patient Identification and the Administration of Oncolytic Viral Therapy, Dr. Howard Kaufman and Dr. Anna C. Pavlick examine the patient and tumor characteristics that may make a patient with advanced melanoma a good candidate for oncolytic viral therapy with or without a checkpoint inhibitor.…

MedEdTalks - Oncology

1
Mechanisms of Oncolytic Viral Therapy With Drs. Howard Kaufman and Kevin Harrington 18:17

منذ 4 years18:17

18:17

Within this podcast, Mechanisms of Oncolytic Viral Therapy, Dr. Howard Kaufman and Professor Kevin Harrington review the rationale for the use of oncolytic viral therapies as monotherapy or in combination with checkpoint inhibitors for patients with advanced melanoma.

MedEdTalks - Oncology

1
Overview of Oncolytic Viral Therapy – Focus on Melanoma With Drs. Howard Kaufman and Dmitriy Zamarin 15:25

منذ 4 years15:25

15:25

Within this podcast, Overview of Oncolytic Viral Therapy – Focus on Melanoma, Dr. Howard Kaufman and Dr. Dmitriy Zamarin evaluate the latest advances regarding the use of oncolytic viral therapy for cancer management, particularly in the context of advanced melanoma.

MedEdTalks - Oncology

1
Oncolytic Viral Therapy – A Look at the Latest Evidence With Drs. Howard Kaufman and Ann Silk 14:56

منذ 4 years14:56

14:56

Within the podcast, Oncolytic Viral Therapy – A Look at the Latest Evidence, Dr. Howard Kaufman and Dr. Ann Silk assess the latest clinical evidence regarding available and emerging oncolytic viral therapies for the management of patients with advanced melanoma.

MedEdTalks - Oncology

1
Updates in Newly-Diagnosed PTCL 14:02

منذ 5 years14:02

14:02

Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. Theses rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss updates in the management of newly diagnosed PTCL. To earn CME credit, follow this link: https://cme.healio.com/mededtalks/hematology-oncology/2019/11_november/mededtalks-oncology-updates-in-newly-diagnosed-ptcl Transcript: https://m1.healio.com/~/media/hyperguides/mededtalks/transcripts/transcript_updates-in-newlydiagnosed-ptcl.pdf…

MedEdTalks - Oncology

1
Antibody-Drug Conjugates in PTCL 15:05

منذ 5 years15:05

15:05

Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast expert clinicians will discuss antibody-drug conjugates in PTCL. To earn CME Credit, please follow this link: https://cme.healio.com/mededtalks/hematology-oncology/2019/11_november/mededtalks-oncology-antibody-drug-conjugates-in-ptcl Transcript: https://m1.healio.com/~/media/hyperguides/mededtalks/transcripts/transcript_antibodydrug-conjugates-in-ptcl.pdf…

MedEdTalks - Oncology

1
Options for Relapsed/Refractory PTCL 24:04

منذ 5 years24:04

24:04

Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss options for managing relapsed/refractory PTCL. To obtain CME Credit, please go here: https://cme.healio.com/mededtalks/hematology-oncology/2019/10_october/mededtalks-oncology-options-for-relapsed-refractory-ptcl…

MedEdTalks - Oncology

1
Updates in Diagnosis of PTCL and the Role of CD30 16:22

منذ 5 years16:22

16:22

Peripheral T-cell lymphomas (PTCLs) are a highly heterogeneous and typically aggressive group of non-Hodgkin lymphomas. These rare tumors represent only 10% to 15% of non-Hodgkin lymphomas and are associated with 5-year survival rates as low as 20% in certain subtypes. Treatment of PTCL has historically consisted of conventional chemotherapy. However, the outcome is poor with this approach. Considerable effort in recent years has focused on identifying improved therapeutic approaches to target PTCLs with greater specificity. In this podcast, expert clinicians will discuss updates in diagnosis of PTCL and the role of CD30. To obtain CME Credit, please go here: https://cme.healio.com/mededtalks/hematology-oncology/2019/10_october/mededtalks-oncology-updates-in-diagnosis-of-ptcl-and-the-role-of-cd30…

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.